giovedì 26 marzo 2009

New Anti-cancer Drug: 200 Times More Active In Killing Tumor Cells

ScienceDaily (Mar. 26, 2009) — A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

The study appears this week in the Journal of the American Chemical Society.
The new agent belongs to a class of drugs called bisphosphonates. These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.
Drug developers have tried for years to design drugs to inhibit cell survival pathways in tumor cells, focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.
Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cancer cells.
When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of breast cancer in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.
But zoledronate quickly binds to bone, reducing its efficacy in other tissues.
"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.
Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous to the use of multi-kinase inhibitors in cancer therapy.
Andrew Wang, of Academia Sinica, Taipei, and Illinois chemist Rong Cao began by producing crystallographic structures of the target enzymes and drug candidates, allowing the researchers to identify those features that would enhance the drugs' ability to bind to the enzymes. Using this and other chemical data, Illinois chemistry department research scientist Yonghui Zhang engineered new bisphosphonate compounds that bound tightly to multiple enzyme targets, but not to bone.
One of the new compounds, called BPH-715, proved to be especially potent in cell culture and effectively inhibited tumor cell growth and invasiveness.
Tadahiko Kubo, of Hiroshima University, then found that BPH-715 also killed tumor cells in mice. And Socrates Papapoulos, of Leiden University, the Netherlands, showed that the compound had a very low chemical affinity for bone.
In humans, compounds like BPH-715 and zoledronate have an added benefit in fighting cancer: They spur the proliferation of immune cells called gamma delta T-cells, which aid in killing tumor cells.
"The new drugs are about 200 times more effective than the drugs used in recent clinical trials at killing tumor cells and in activating gamma delta T-cells to kill tumor cells," Oldfield said. "They also prevent tumor progression in mice much better than do existing bisphosphonate molecules."
Journal reference:
Zhang et al. Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation. Journal of the American Chemical Society, 2009; 090323145321030 DOI: 10.1021/ja808285e
Adapted from materials provided by University of Illinois at Urbana-Champaign.

1 commento:

phyl ha detto...

This is great information. We need more people investing in their health using their own adult stem cells. There is a product out for everyone today; it has been on the market for over three years and 5 years in testing. Stem Cells from your bone marrow are available now. I would like to introduce you to the World’s First Stem Cell Enhancer. It is proven by Science and Medical Teams in a Peer Review study.
“The Cardiovascular Revascularization Medicine” “ 8 (2007) 189–202”

Please take the tour and down load the study. I can send you more educational information on this amazing product. Adult Stem Cells can become any organ, tissue, or muscle in the body. After taking 1 gram of StemEnhance your body releases 3 to 4 million adult stem cells, into the blood stream. This is the body’s natural way to renew, refresh, and rejuvenate itself. We are unleashing a whole new system of the body that has always been there. This is an all natural botanical extract for everyone..http://www.phyl247.biz office 970-985-4076 or 877-696-8581